Suscribirse

Protective effect of Xin-Ji-Er-Kang on cardiovascular remodeling in high-salt induced hypertensive mice: Role ofoxidative stress and endothelial dysfunction - 09/06/19

Doi : 10.1016/j.biopha.2019.108937 
Xiao-yun Wang a, 1, Guang-yao Huang a, 1, Feng-zhen Lian a, 1, Ming Pan a, 1, Cheng-shao Ruan a, Xin-xin Ling a, Mei-ling Chen b, Ai-zong Shen c, , Shan Gao a,
a Department of Pharmacology, Basic Medical College, Anhui Medical University, Hefei 230032, PR China 
b Cancer Hospital, Chinese Academy of Sciences,Hefei 230032, PR China 
c The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, PR China 

Corresponding authors.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 11
Iconografías 9
Vídeos 0
Otros 0

Highlights

A high-salt diet induces hypertension, which eventually leads to cardiovascular remodeling.
High-salt induced hypertensive mice have obvious oxidative stress and endothelial dysfunction.
As a prescription that has been used in clinical practice for many years,Xin-Ji-Er-Kanghas the function of antioxidant and balance endothelin system.
XJEK mitigates cardiac remodeling in high-salt-induced hypertensive mice.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

Xin-Ji-Er-Kang (XJEK) is a Chinese herbal formula that has beenreported to exert effective protection against cardiovascular diseases, such as hypertension and myocarditis.

Objective

The aim of the present study was to investigate the effect of XJEK on high-salt-induced hypertensive mice and its possible mechanism.

Methods

The model of hypertension was established through a high-salt diet. Sixty male Kunming mice were randomized into six groups, namely the Control, Model, Low-dose XJEK, Middle-dose XJEK, High-dose XJEK and Fosinopril groups (n=10 per group). Different steady interventions were given to each group: 0.9% Sodium chloride was added to the diet of the Control group and 8% sodium chloride to the diet of the other five groups from the very beginning. An additional 4, 8 and 12 g/kg/day XJEK were intragastrically administered to the Low-dose, Middle-dose and High-dose XJEK groups, respectively, and 2 mg/kg/day fosinopril to the fosinopril group, from the start of week 5. Systolic blood pressure (SBP) was measured weekly from weeks 1 to 8 using the tail-cuff method. At the end of week 8, left ventricular (LV) systolic pressure, LV end-diastolic pressure and rate of rise of LV pressure were examined using a TransonicScisense catheter (Transonic Systems Inc,Ithaca, NY,USA). Endothelium-dependent relaxations induced by acetylcholine were observed in an isolated thoracic aorta ring. Serum and heartsweresampled for the measurement of the following indexes:Serum nitric oxide (NO), superoxide dismutase (SOD) activity and malondialdehyde (MDA) content (determined by colorimetricanalysis); serum angiotensin II(Ang II), endothelin-1, endothelial NO synthase (eNOS), asymmetric dimethylarginine (ADMA), tetrahydrobiopterin (BH4) concentration and l-arginine (determined by enzyme-linked immunosorbent assay); heart to body weight (HW/BW) ratio; myocardial morphological change (determined by HE and VG staining); myocardial eNOS expression (determined by immunofluorescence), and myocardial endothelin receptor A (ETA) expression (determined by western blotting).

Results:Statistical data showed that the HW/BW ratio was significantly decreased in the drug treatment group. XJEK treatment could improve the heart systolic and diastolic function and ameliorate hemodynamic parameters and vascular remodeling indexes. Colorimetric results showed that, compared with the model group, XJEK increased serum SOD, NOlevels, and decreased those of serum MDA and Ang II. XJEK reverted changes in cardiac pathology, decreased the myocardial cross-sectional area, collagen volume fraction and perivascular collagen area and improved endothelial dysfunction (ED) by promoting eNOS activity, enhancing NO bioavailability, increasing the expression of BH4 and decreasing ETA content. In addition, treatment with XJEK decreased ADMA content in the myocardium.

Conclusion:In conclusion, XJEK mitigates cardiac remodeling in high-salt-induced hypertensive mice. The potential mechanism involves improved oxidative stress and endothelial dysfunction, independently of ameliorating BP.

El texto completo de este artículo está disponible en PDF.

Abbreviations : XJEK, LV, LVH, CR, SBP, LVSP, LVEDP, ±dp/dtmax, RAS, HE, VG, CSA, TAA, AR, MT, ELISA, ED, ET-1, ETA, NO, eNOS, OS, ROS, SOD, MDA, BH4, AngII, ADMA, l-Arg, HW/BW, WB

Keywords : Hypertension, Cardiac remodeling, Endothelial dysfunction, Oxidative stress


Esquema


© 2019  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 115

Artículo 108937- juillet 2019 Regresar al número
Artículo precedente Artículo precedente
  • Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway
  • Qiongyan Lin, Hui Chen, Minfen Zhang, Hanzhen Xiong, Qingping Jiang
| Artículo siguiente Artículo siguiente
  • Apigenin relaxes rat intrarenal arteries, depresses Ca2+-activated Cl? currents and augments voltage-dependent K+ currents of the arterial smooth muscle cells
  • Yixin Jing, Rui Chen, Miaomiao Dong, Yu Liu, Xiaomin Hou, Pengmei Guo, Weiping Li, Jiyuan Lv, Mingsheng Zhang

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.